A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence

Table 2 38G model performance compared to CAPRA-S for association with BCR in the training cohort (n = 100)

	Sensitivity	Specificity	PPV	NPV
Overall BCR
38G	94.44	92.31	92.73	94.12
CAPRA-S	37.74	94	86.96	58.75
BCR within 1.5 years
38G	100	62.65	42.59	100
CAPRA-S	52.17	86.25	52.17	86.25
BCR within 3 years
38G	95.35	79.37	75.93	96.15
CAPRA-S	41.86	91.67	78.26	68.75
BCR within 5 years
38G	94.12	89.09	88.89	94.23
CAPRA-S	40	94.34	86.96	62.5
BCR within 7 years
38G	92.31	88.89	88.89	92.31
CAPRA-S	39.22	94.23	86.96	61.25

ISSN: 1471-2407